Pharmacologic and cytokinetic studies of arabinosyl cytosine.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D002464:Cell Migration Inhibition; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004247:DNA / Q000037:antagonists & inhibitors; D004254:DNA Nucleotidyltransferases / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008213:Lymphocyte Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008938:Mitosis / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D004247:DNA; D004254:DNA Nucleotidyltransferases; D011241:Prednisone